Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 2.772 EUR 0.58% Market Closed
Market Cap: 463.7m EUR

Relative Value

The Relative Value of one VLA stock under the Base Case scenario is 4.965 EUR. Compared to the current market price of 2.772 EUR, Valneva SE is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLA Relative Value
Base Case
4.965 EUR
Undervaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
70
Median 3Y
2.1
Median 5Y
2.8
Industry
6.9
Forward
2.2
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-15.3
Industry
23
Forward
-11
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-2.3
Industry
19.7
vs History
vs Industry
Median 3Y
-4
Median 5Y
-3.1
Industry
22.8
vs History
90
vs Industry
31
Median 3Y
3.6
Median 5Y
4.7
Industry
2.6
vs History
79
vs Industry
60
Median 3Y
2.1
Median 5Y
2.6
Industry
7.4
Forward
2.4
vs History
96
vs Industry
45
Median 3Y
6.6
Median 5Y
7.9
Industry
9.3
vs History
vs Industry
8
Median 3Y
-7.2
Median 5Y
-9.6
Industry
4.1
Forward
-10.8
vs History
vs Industry
4
Median 3Y
-6.1
Median 5Y
-15
Industry
4.1
Forward
-7.7
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.3
Industry
4.9
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-2.4
Industry
3.6
vs History
88
vs Industry
48
Median 3Y
1.9
Median 5Y
2.2
Industry
4.7

Multiples Across Competitors

VLA Competitors Multiples
Valneva SE Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Valneva SE
PAR:VLA
450.2m EUR 1.7 -14.7 -93.5 -93.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 726 477.3 -165 049.8 -200 423.1 -198 136
US
Abbvie Inc
NYSE:ABBV
331.1B USD 5.8 79.7 15.2 22.5
US
Amgen Inc
NASDAQ:AMGN
154.4B USD 4.5 26 14.1 23.2
US
Gilead Sciences Inc
NASDAQ:GILD
137.7B USD 4.8 23.1 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD 10.3 -115.8 24.6 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 028.7 -517.7 -563.7 -548.7
AU
CSL Ltd
ASX:CSL
117.6B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
52.3B USD 3.7 11.6 10.2 11.5
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.9 -64.6 -58.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40B USD 17 -148.4 -664.4 -332.9
P/S Multiple
Revenue Growth P/S to Growth
FR
Valneva SE
PAR:VLA
Average P/S: 3 157 143.5
1.7
31%
0.1
FR
Pharnext SCA
OTC:PNEXF
34 726 477.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 028.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.7
5%
0.7
US
S
Seagen Inc
F:SGT
19.5
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17
29%
0.6
P/E Multiple
Earnings Growth PEG
FR
Valneva SE
PAR:VLA
Average P/E: 33.6
Negative Multiple: -14.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 049.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.7
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Valneva SE
PAR:VLA
Average EV/EBITDA: 15.2
Negative Multiple: -93.5
26%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 423.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -664.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Valneva SE
PAR:VLA
Average EV/EBIT: 19.7
Negative Multiple: -93.5
86%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 136 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.2
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -332.9 N/A N/A